{
  "ticker": "JNJ",
  "target_date": "2025-05-09",
  "actual_date": "2025-05-09",
  "collected_at": "2025-12-08T11:44:47.430972",
  "price": {
    "open": 152.01,
    "high": 152.64,
    "low": 150.44,
    "close": 150.8372344970703,
    "volume": 6520400,
    "change_1d_pct": -0.93,
    "change_7d_pct": -1.34,
    "change_30d_pct": -5.46
  },
  "technicals": {
    "rsi_14": 41.96,
    "sma_20": 151.87,
    "sma_50": 155.32,
    "macd": -0.53,
    "macd_signal": -0.725,
    "macd_histogram": 0.195,
    "bb_upper": 154.75,
    "bb_lower": 148.99,
    "price_vs_sma20_pct": -0.68,
    "price_vs_sma50_pct": -2.89,
    "volume_ratio": 0.82
  },
  "fundamentals": {
    "market_cap": 489038708736,
    "pe_ratio": 19.592665,
    "forward_pe": 19.149055,
    "price_to_book": 6.160804,
    "price_to_sales": 5.307043,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.32,
    "pct_from_52w_low": 44.28
  },
  "macro": {
    "spy": {
      "price": 561.12,
      "change_1d_pct": -0.13,
      "change_7d_pct": 1.05
    },
    "vix": {
      "level": 21.9,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.38
    },
    "dollar_index": {
      "level": 100.34
    },
    "gold": {
      "price": 3335.4
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (NYSE:JNJ) Announces Positive Trial Results Amid Legal Setback",
      "source": "Yahoo",
      "datetime": 1746811368,
      "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment for psoriasis, while facing legal challenges from a jury awarding a $3 million verdict linked to baby powder use. These developments coincided with a 3.77% rise in the company's",
      "url": "https://finnhub.io/api/news?id=bd942dfbe8ce88f2fce8b0afa9638de00ce2f7feecc6c0006e45f53da28745aa"
    },
    {
      "headline": "Pharma Worries Shift to Prices From Trade. Trump\u2019s Next Plan Could Sink Stocks.",
      "source": "MarketWatch",
      "datetime": 1746809460,
      "summary": "Pharma Worries Shift to Prices From Trade. Trump\u2019s Next Plan Could Sink Stocks.",
      "url": "https://finnhub.io/api/news?id=ac42ac8bc85d73493d6981014a986e53594cf61c1bfd01b8285a21aa7f5271a9"
    },
    {
      "headline": "Health Care Roundup: Market Talk",
      "source": "DowJones",
      "datetime": 1746794460,
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=2fc83c556432825123456430cf0d4e06bfb749fc4d99be2fc3fb6172e60d4bba"
    },
    {
      "headline": "J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study",
      "source": "Yahoo",
      "datetime": 1746792845,
      "summary": "The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals.  J&J said last month it expects the drug, icotrokinra, to generate sales of $700 million in 202",
      "url": "https://finnhub.io/api/news?id=cb600eec5c855a10afd8da5ceb58f831fb8f17ce7757a6afb9c0a7265300c47d"
    },
    {
      "headline": "Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis",
      "source": "Yahoo",
      "datetime": 1746792300,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated adults and adolescents 12 years of age and older ",
      "url": "https://finnhub.io/api/news?id=0425b5855872ad4dd0658ad1d6be20ed2a4fee14080d086764923558f7de7b69"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    },
    {
      "form": "8-K",
      "date": "2025-04-30",
      "description": "jnj-20250424.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000141/jnj-20250424.htm"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877468.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000138/xslF345X05/wk-form4_1745877468.xml"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877247.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000135/xslF345X05/wk-form4_1745877247.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}